ChemoCentryx Inc (NASDAQ:CCXI)’s share price rose 5.6% during trading on Friday . The company traded as high as $41.17 and last traded at $43.22, approximately 65,841 shares were traded during mid-day trading. A decline of 91% from the average daily volume of 743,200 shares. The stock had previously closed at $40.93.
CCXI has been the subject of a number of research analyst reports. HC Wainwright lifted their target price on ChemoCentryx from $23.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “hold” rating in a report on Friday, January 3rd. Piper Jaffray Companies lifted their target price on ChemoCentryx from $17.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, November 26th. Raymond James lifted their target price on ChemoCentryx from $17.00 to $56.00 and gave the stock a “strong-buy” rating in a report on Tuesday, November 26th. Finally, ValuEngine lowered ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $40.29.
The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $34.83 and a 200 day moving average of $14.87.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. The company had revenue of $10.58 million during the quarter, compared to analyst estimates of $7.83 million. On average, analysts forecast that ChemoCentryx Inc will post -0.98 EPS for the current fiscal year.
In other ChemoCentryx news, CEO Thomas J. Schall sold 279,166 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $31.55, for a total transaction of $8,807,687.30. Following the completion of the sale, the chief executive officer now owns 2,508,021 shares of the company’s stock, valued at $79,128,062.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pui San Kwan sold 1,000 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $39.02, for a total value of $39,020.00. Following the sale, the insider now directly owns 20,434 shares of the company’s stock, valued at approximately $797,334.68. The disclosure for this sale can be found here. Insiders sold 1,161,538 shares of company stock valued at $37,814,838 in the last ninety days. 12.20% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC bought a new stake in ChemoCentryx during the second quarter valued at about $29,000. JPMorgan Chase & Co. grew its holdings in ChemoCentryx by 104.2% during the second quarter. JPMorgan Chase & Co. now owns 11,191 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 5,710 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in ChemoCentryx by 70.2% during the third quarter. Metropolitan Life Insurance Co NY now owns 14,981 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 6,177 shares during the period. SG Americas Securities LLC grew its holdings in ChemoCentryx by 26.0% during the third quarter. SG Americas Securities LLC now owns 25,418 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 5,247 shares during the period. Finally, UBS Asset Management Americas Inc. bought a new stake in ChemoCentryx during the second quarter valued at about $201,000. 60.72% of the stock is owned by institutional investors and hedge funds.
ChemoCentryx Company Profile (NASDAQ:CCXI)
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More: Why do earnings reports matter?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.